Q-omics provides the consensus-scored CHIT1 profile across patient tissues and cancer cell-line models. CHIT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, CHIT1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CHIT1 protein abundance shows 17,403 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, KIRC, and GBM as cancer lineages where CHIT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHIT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHIT1 survival associations across molecular data types. CHIT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHIT1 RNA expression–survival associations across cancer types. High CHIT1 expression shows favorable associations in CESC, LUAD, HNSC, DLBC, KIRC and KIRP. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for CHIT1 RNA expression.
This table summarizes CHIT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CHIT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHIT1 shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, STAD, KIRP and BLCA. The KIRC box plot shows higher CHIT1 RNA expression in tumor versus normal tissue (log2 FC = +1.953, t-test p < 0.001).
This table shows molecular features associated with CHIT1 in patient tissues and cancer cell lines. In patient samples, CHIT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHIT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
